Detail

Study ID: Alliance A051701

Title:

Randomized Phase II/III Study of Venetoclax (ABT-199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Location:
Bismarck Region, Fargo Region, Sioux Falls Region
Principal Investigator:
Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Disease:
NHL (Non-Hodgkins Lymphoma)
Stage:
Phase II/III
Status:
Active - Open to Accrual